Baseline Characteristics of Included Patients. حسب Mohamed R. Abdelraouf (21501468)

الموضوعات:

Data for Fig 6D. حسب Xiaohua Zhang (350570)

الموضوعات:

Sensitivity analysis. حسب Jiuming Li (11711375)

الموضوعات:

Characteristics of participants. حسب Jiuming Li (11711375)

الموضوعات:

Data for Fig 5D. حسب Xiaohua Zhang (350570)

الموضوعات:

Participant Flowchart. حسب Jiuming Li (11711375)

الموضوعات:

Stratified analyses. حسب Jiuming Li (11711375)

الموضوعات:

Effect of AUT00201 (1 µM) on PV properties after juvenile demyelination. حسب Sara Hijazi (21656615)

الموضوعات:

PRV UL4 protein facilitates ASC oligomerization and speck formation by promoting ASC phosphorylation. حسب Xiaohua Zhang (350570)

الموضوعات:

Synthesis and Preclinical Evaluation of Novel ^99mTc-Labeled FR-Targeting Agents with Satisfactory Imaging Contrast and Reduced Renal Uptake حسب Junhong Feng (11835903)

الموضوعات:

Amorphous Silica/NaNbO₃ Crystal Heterophase Junction-Supported Ru Catalyst with Optimized Surface and Electron Structure for Highly Efficient Hydrogenation of α‑Pinene... حسب Haozhang Xu (21366415)

الموضوعات:

Standardized estimation of centrality index. حسب Song Chen (69646)

الموضوعات:

Sequence of UL4 is involved in inflammasome activation. حسب Xiaohua Zhang (350570)

الموضوعات:

The UL4 mutation alleviated inflammasome activation and pyroptosis in PRV-infected cells. حسب Xiaohua Zhang (350570)

الموضوعات:

PRV UL4 interacts with ASC. حسب Xiaohua Zhang (350570)

الموضوعات:

The UL4 mutation alleviates inflammation in PRV-infected pigs. حسب Xiaohua Zhang (350570)

الموضوعات:

The UL4 null mutation alleviates inflammasome activation in PRV-infected cells. حسب Xiaohua Zhang (350570)

الموضوعات:

The UL4 mutation alleviated inflammation in PRV-infected mice. حسب Xiaohua Zhang (350570)

الموضوعات:

The UL4 mutation alleviates inflammasome activation and pyroptosis in PRV-infected cells. حسب Xiaohua Zhang (350570)

الموضوعات:

The UL4 null mutation alleviated inflammasome activation in PRV-infected cells. حسب Xiaohua Zhang (350570)

الموضوعات: